Sompharmaceuticals acquired by Amryt

Please login or
register

Stefan Kyora

13.05.2016

Amryt Pharma, a specialty pharmaceutical company listed on the London Stock exchange, has acquired Sompharmaceuticals, a Swiss start-up based in Epalinges.

Amryt was incorporated in August 2015 as a platform to acquire, build, develop and subsequently monetise a pipeline of patent protected, commercially attractive, proprietary drug candidates targeting best in class performance chosen to meet the Orphan Drug Designation criteria. In April 2016 Amryt Pharma joined AIM after a reverse takeover of Fastnet.

Where appropriate, Amryt will commercialise the drugs it successfully develops through its own salesforce. In line with this strategy, Amryt has entered into an agreement to acquire SomPharmaceuticals.

Sompharmaceuticals is a Swiss based biopharmaceutical company focused on developing novel somatostatin analogue peptide medicines for patients with rare neuroendocrine diseases with high unmet need, principally focused on additional orphan drug candidates to address acromegaly and Cushing's disease. The company is based at the Biopôle in Epalinges-Lausanne. The company was founded by a highly experienced team. Chairman and Founder Alan G. Harris is a R&D professional with strong foundation in clinical design, planning and execution; with extensive experience Phase I though IV clinical programs for pivotal regulatory and marketing trials (conducted and oversaw hundreds of trials in over 30 countries) and with a strong network of colleagues among key opinion leaders.

0Comments

More news about

Sompharmaceuticals SA

Company profiles on startup.ch

Sompharmaceuticals SA

rss